Tacrolimus in pediatric liver transplantation
Raymond Reding,
Raymond Reding
Search for more papers by this authorRaymond Reding,
Raymond Reding
Search for more papers by this authorFirst published: 17 September 2008
Citations: 11
References
- 1 Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces Tsukubaensis. Transplant Proc 1987: 19: 4–8.
- 2 Goto T, Kino T, Hatanaka H, et al. FK 506: Historical perspectives. Transplant Proc 1991: 23: 2713–2717.
- 3 Wallemacq P, Reding R. FK 506 (Tacrolimus), a novel immunosuppressant in organ transplantation: Clinical, biomedical and analytical aspects. Clin Chem 1993: 39: 2219–2228.
- 4 Ochiai T, Nagata M, Nakajima K, Sakamoto K, Asano T, Isono K. Prolongation of canine renal allograft survival by treatment with FK-506. Transplant Proc 1987: 19: 53–56.
- 5 Calne R, Collier J, Thiru S. Observations about FK-506 in primates. Transplant Proc 1987: 19: 63.
- 6 Todo S, Ueda Y, Demetris JA, et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: With special reference to synergism with other drugs and to tolerance induction. Surgery 1988: 104: 239–249.
- 7 Kelly DA, Jara P, Rodeck B, et al. Tacrolimus dual therapy versus cyclosporin-microemulsion triple therapy in paediatric liver transplantation: Results from a multicentre randomized trial. Am J Transplant 2002: 2: 351.
- 8 Francavilla A, Barone M, Todo S, Zeng Q, Porter KA, Starzl TE. Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet 1989: ii: 1248–1249.
- 9 Dhar DK, Nagasue N, Kimoto T, Uchida M, Takemoto Y, Nakamura T. The salutary effect of FK 506 in ischemia-reperfusion injury of the canine liver. Transplantation 1992: 54: 583–588.
- 10
Starzl TE,
Todo S,
Fung JJ,
Demetris AJ,
Venkataramanan R,
Jain A.
FK 506 for liver, kidney, and pancreas transplantation.
Lancet
1989: ii: 1000–1004.
10.1016/S0140-6736(89)91014-3 Google Scholar
- 11 Starzl TE. The drug with no name. Transplant Proc 1991: 23: 2709.
- 12 Todo S, Fung JJ, Tzakis A, et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc 1991: 23: 1397–1402.
- 13 Fung JJ, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991: 23: 2977–2983.
- 14 The U.S. Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994: 331: 1110–1115.
- 15 The European FK 506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994: 344: 423–428.
- 16 Jain A, Pokharna R, Mazariegos G, et al. Tacrolimus offers almost total absence of chronic rejection in pediatric liver transplant recipient: Follow-up of 7–10 years. Am J Transplant 2002: 2: 352.
- 17 Tzakis A, Reyes J, Todo S, et al. FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991: 23: 3010–3015.
- 18 McDiarmid S, Klintmalm GB, Busuttil RW. FK 506 rescue therapy in liver transplantation: Outcome and complications. Transplant Proc 1991: 23: 2996–2999.
- 19 Reding R, De Ville de Goyet J, Sokal E, et al. Compassionate use of FK 506 in pediatric liver transplantation: A pilot study. Transplant Proc 1991: 23: 3002–3004.
- 20 Reding R, Wallemacq P, Lamy ME, et al. Conversion from cyclosporine A to FK 506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity and dose regimen in 23 children. Transplantation 1994: 57: 93–100.
- 21 Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000: 69: 2573–2580.
- 22 Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation 2000: 70: 617–625.
- 23 Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: Comparison between cyclosporine A and tacrolimus. Pediatr Transpl 1999: 3: 22–26.
- 24 Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996: 61: 247–252.
- 25 Reding R, De Ville de Goyet J, Delbeke I, et al. Pediatric liver transplantation with cadaveric or living related donors: Comparative results in 90 elective recipients of primary grafts. J Pediatr 1999: 134: 280–286.
- 26 McDiarmid S, Busuttil RW, Ascher N, et al. FK 506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation 1995: 59: 530–536.
- 27 Savoldi E, Rolfi A, Majorana A, Alberti D. Dental and oral aspects in pediatric liver transplant patients. A comparison between the effects of cyclosporine A and FK 506. Minerva Stomatol 1997: 46: 73–77.
- 28 Thorp M, Demattos A, Bennett W, Barry J, Norman DJ. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation 2000: 69: 1218–1224.
- 29 O'Gorman MA, Fivush B, Wise B, Colombani P, Burdick J, Schwarz KB. Proximal renal tubular acidosis secondary to FK506 in pediatric liver transplant patients. Clin Transpl 1995: 9: 312–316.
- 30 Tabasco-Minguillan J, Mieles L, Carroll P, Gavaler J, Van Thiel DH, Starzl TE. Insulin requirements after liver transplantation and FK-506 immunosuppression. Transplantation 1993: 56: 862–867.
- 31 Carroll PB, Rilo H, Reyes J, et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. Transplant Proc 1991: 23: 3171–3172.
- 32 Atkison P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 2002: 345: 894–896.
- 33 Atkison P, Joubert G, Guiraudon C, et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. Transplantation 1997: 64: 773–775.
- 34 Reyes J, Tzakis A, Green M, et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc 1991: 23: 3044–3046.
- 35 Frayha HH, Nazer H, Kalloghlian A, Antonius JI, Sabbah R. Lymphoproliferative disorder in a liver transplant patient on FK 506. Lancet 1991: 337: 296–297.
- 36 Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein–Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995: 59: 524–529.
- 37 Sokal E, Caragiozoglou T, Lamy ME, Reding R, Otte JB. Epstein–Barr virus serology and Epstein–Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients. Transplantation 1993: 56: 1394–1398.
- 38 Burman K, Crawford DH. Effect of FK 506 on Epstein–Barr virus specific cytotoxic T cells. Lancet 1991: 337: 297–298.
- 39 Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK 506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transpl 2001: 5: 359–364.
- 40 Smets F, Bodeus M, Goubau P, et al. Characteristics of Epstein–Barr virus primary infection in pediatric liver transplant recipients. J Hepatol 2000: 32: 100–104.
- 41 Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK 506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996: 61: 1188–1192.
- 42 Wallemacq P, Furlan V, Moller A, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet 1998: 23: 367–370.
- 43 Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2002: 72: 1056–1061.
- 44 Hochleitner BW, Bosmuller C, Nehoda H, et al. Increased tacrolimus levels during diarrhea. Transpl Int 2001: 14: 230–233.
- 45 Frühwirth M, Fischer H, Simma B, Ellemunter H. Elevated tacrolimus trough levels in association with mycophenolate mofetil-induced diarrhea: A case report. Pediatr Transpl 2001: 5: 132–134.
- 46 Frühwirth M, Fischer H, Simma B, et al. Rotavirus infection as cause of tacrolimus elevation in solid-organ-transplanted children. Pediatr Transpl 2001: 5: 88–92.
- 47 Mittal N, Thompson JF, Kato T, Tzakis A. Tacrolimus and diarrhea: Pathogenesis of altered metabolism. Pediatr Transpl 2001: 5: 75–79.
- 48 Esquivel C, So S, McDiarmid S, Andrews WS, Colombani P. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. Transplantation 1996: 61: 847–848.
- 49 Reding R, Sokal E, Paul K, et al. Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. Pediatr Transpl 2002: 6: 124–126.
- 50 Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998: 351: 1701–1702.
- 51 Reding R, Feyaerts A, Vraux H, et al. Prophylactic immunosuppression with anti-IL-2 receptor monoclonal antibody LO-Tact-1 versus OKT3 in liver allografting. A two year follow-up study. Transplantation 1996: 61: 1406–1409.
Citing Literature
